These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8253340)

  • 21. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
    Feith M; Stein HJ; Mueller J; Siewert JR
    Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 protein accumulation predicts malignant progression in Barrett's metaplasia: a prospective study of 275 patients.
    Younes M; Brown K; Lauwers GY; Ergun G; Meriano F; Schmulen AC; Barroso A; Ertan A
    Histopathology; 2017 Jul; 71(1):27-33. PubMed ID: 28226185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation.
    Chinyama CN; Marshall RE; Owen WJ; Mason RC; Kothari D; Wilkinson ML; Sanderson JD
    Histopathology; 1999 Dec; 35(6):517-24. PubMed ID: 10583575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
    Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
    Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Does the criterium of positivity for the immunohistochemical analysis of p53 in the confirmation of Barrett's dysplasia make any difference?].
    Lopes CV; Pereira-Lima JC; Hartmann AA; Tonelotto E; Salgado K
    Arq Gastroenterol; 2005; 42(4):233-8. PubMed ID: 16444378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7.
    Symmans PJ; Linehan JM; Brito MJ; Filipe MI
    J Pathol; 1994 Jul; 173(3):221-6. PubMed ID: 7931842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
    Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
    Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant p53 Immunostaining in Barrett's Esophagus Predicts Neoplastic Progression: Systematic Review and Meta-Analyses.
    Snyder P; Dunbar K; Cipher DJ; Souza RF; Spechler SJ; Konda VJA
    Dig Dis Sci; 2019 May; 64(5):1089-1097. PubMed ID: 30911864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus.
    Moyes LH; McEwan H; Radulescu S; Pawlikowski J; Lamm CG; Nixon C; Sansom OJ; Going JJ; Fullarton GM; Adams PD
    J Pathol; 2012 Sep; 228(1):99-112. PubMed ID: 22653845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 'angiogenic switch' in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
    Möbius C; Stein HJ; Becker I; Feith M; Theisen J; Gais P; Jütting U; Siewert JR
    Eur J Surg Oncol; 2003 Dec; 29(10):890-4. PubMed ID: 14624783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus.
    Hamelin R; Fléjou JF; Muzeau F; Potet F; Laurent-Puig P; Fékété F; Thomas G
    Gastroenterology; 1994 Oct; 107(4):1012-8. PubMed ID: 7523212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia.
    Younes M; Ertan A; Lechago LV; Somoano JR; Lechago J
    Dig Dis Sci; 1997 Apr; 42(4):697-701. PubMed ID: 9125634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of the p53 homologue p63alpha and DeltaNp63alpha in the neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein.
    Hall PA; Woodman AC; Campbell SJ; Shepherd NA
    Gut; 2001 Nov; 49(5):618-23. PubMed ID: 11600462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53--prognostic factor of malignant transformation of Barrett's esophagus.
    Aujeský R; Hajdúch M; Neoral C; Král V; L'ubusská L; Bohanes T; Klein J; Vrba R; Drác P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Jun; 149(1):141-4. PubMed ID: 16170400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma.
    Morales CP; Lee EL; Shay JW
    Cancer; 1998 Aug; 83(4):652-9. PubMed ID: 9708927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
    Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
    Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical study of p53, c-erbB-2, and PCNA in barrett's esophagus with dysplasia and adenocarcinoma arising from experimental acid or alkaline reflux model.
    Kawaura Y; Tatsuzawa Y; Wakabayashi T; Ikeda N; Matsuda M; Nishihara S
    J Gastroenterol; 2001 Sep; 36(9):595-600. PubMed ID: 11578062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases.
    Schneider PM; Casson AG; Levin B; Garewal HS; Hoelscher AH; Becker K; Dittler HJ; Cleary KR; Troster M; Siewert JR; Roth JA
    J Thorac Cardiovasc Surg; 1996 Feb; 111(2):323-31; discussion 331-3. PubMed ID: 8583805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.